17th Dec 2009 07:00
|
For immediate release |
17 December 2009 |
ABCAM PLC
("Abcam" or "the Company")
Pre-Close Trading Update
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is pleased to announce a pre-close trading update ahead of its results for the six months ending 31 December 2009.
Trading since the Company's statement to the Annual General Meeting at the beginning of November has been very good, and brings to a close what is expected to be a successful first six months of the financial year across the business. Results have been particularly boosted by favourable exchange rates compared with last year.
Although recent levels of trading may be attributable in part to scientists utilising budgets before the end of December, the Board has made an upwards revision of its expectations for the full year. These revised expectations are subject to the continued resilience of our markets to any downturn in scientific research budgets as a consequence of the global recession and assumptions of future exchange rates.
The Company will report its interim results for the six months ending 31 December 2009 in the week commencing 8 March 2010.
For further information please contact:
|
Abcam
|
+ 44 (0) 1223 696000
|
|
Jonathan Milner, Chief Executive Officer
|
|
|
Jeffrey Iliffe, Chief Financial Officer
www.abcam.com
|
|
|
|
|
|
Numis Securities
|
+ 44 (0) 20 7260 1000
|
|
Michael Meade / Nick Westlake - Nominated Adviser
|
|
|
James Black - Corporate Broking
|
|
|
|
|
|
Buchanan Communications
|
+ 44 (0) 20 7466 5000
|
|
Mark Court / Stasa Filiplic
|
|
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with offices located in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 57,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs over 250 staff in its four operating companies.
Related Shares:
ABC.L